A comparative safety review of histone deacetylase inhibitors for the treatment of myeloma

References

• Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358:1148–1159.
   PubMed Web of Science ®Google Scholar
• Smith EM, Boyd K, Davies FE. The potential role of epigenetic therapy in multiple myeloma. Br J Haematol. 2009;148:702–713.
   PubMed Web of Science ®Google Scholar
• Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol. 2004;338:17–31.
   PubMed Web of Science ®Google Scholar
• Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150:12–27.
   PubMed Web of Science ®Google Scholar
• Kaufman JL, Fabre C, Lonial S, et al. Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy. Clin Lymphoma Myeloma Leuk. 2013;13:370–376.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Moreau P, Laubach JP, et al. Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma. Pharmacol Res. 2016;117:185–191.
   PubMed Web of Science ®Google Scholar
• Harada T, Hideshima T, Anderson KC. Histone deacetylase inhibitors in multiple myeloma: from bench to bedside. Int J Hematol. 2016;104:300–309.
   PubMed Web of Science ®Google Scholar
• Walker BA, Wardell CP, Chiecchio L, et al. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood. 2011;117(2):553–562.
   PubMed Web of Science ®Google Scholar
• Walker BA, Boyle EM, Wardell CP, et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol. 2015;33:3911–3920.
   PubMed Web of Science ®Google Scholar
• Seidl S, Ackermann J, Kaufmann H, et al. DNA-methylation analysis identifies the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies. Cancer. 2004;100:2598–2606.
   PubMed Web of Science ®Google Scholar
• Xu W, Ngo L, Perez G, et al. Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci USA. 2006;103:15540–15545.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA. 2005;102:8567–8572.
   PubMed Web of Science ®Google Scholar
• Cea M, Cagnetta A, Gobbi M, et al. New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. Curr Pharm Des. 2013;19:734–744.
   PubMed Web of Science ®Google Scholar
• Zain J. Role of histone deacetylase inhibitors in the treatment of lymphomas and multiple myeloma. Hematol Oncol Clin N Am. 2012;26:671–704.
   PubMed Web of Science ®Google Scholar
• Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev. 2003;29:3–9.
   PubMed Web of Science ®Google Scholar
• Chhabra S. Novel proteasome inhibitors and histone deacetylase inhibitors: progress in myeloma therapeutics. Pharmaceuticals. 2017;10:40.
   Web of Science ®Google Scholar
• Richardson PG, Mitsiades C, Laubach JP, et al. Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk Res. 2013;37:829–837.
   PubMed Web of Science ®Google Scholar
• Chesi M, Palmer S, Garbitt V, et al. The Vk*MYC mouse model of myeloma identifies successful combination therapies for the treatment of bortezomib refractory myeloma patients. Blood. 2010;116:3015.
   Web of Science ®Google Scholar
• Anne M, Sammartino D, Barginear M, et al. Profile of panobinostat and its potential for treatment in solid tumors: an update. Onco Targets Ther. 2013;6:1613–1624.
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Richardson PG, et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood. 2003;101:4055–4062.
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals Corporation. Farydak (panobinostat). East Hanover (NJ); p. 07936.
   Google Scholar
• Clive S, Woo M, Nydam T, et al. Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients. Cancer Chemother Pharmacol. 2012;70:513–522.
   PubMed Web of Science ®Google Scholar
• Hamberg P, Woo M, Chen L, et al. Effect of ketoconazole- mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), a orally active histone deacetylase inhibitor. Cancer Chemother Pharmacol. 2011;68:805–813.
   PubMed Web of Science ®Google Scholar
• Giles F, Fischer T, Cortes J, et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2006;12:4628–4635.
   PubMed Web of Science ®Google Scholar
• Prince HM, Bishton MJ, Johnstone RW. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol. 2009;5(5):601–612.
   PubMed Web of Science ®Google Scholar
• DeAngelo D, Spencer A, Bhalla K, et al. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia. 2013;27:1628–1636.
   PubMed Web of Science ®Google Scholar
• Wolf J, Siegel D, Goldschmidt H, et al. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma. 2012;53:1820–1823.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Richardson PG, Gunther A, et al. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol. 2013;31:3696–3703.
   PubMedGoogle Scholar
• Garnock-Jones KP. Panobinostat: first global approval. Drugs. 2015;75:695–704.
   PubMed Web of Science ®Google Scholar
• Richardson P, Schlossman R, Alsina M, et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory patients. Blood. 2013;122:1223–1237.
   Web of Science ®Google Scholar
• San-Miguel J, Hungria V, Yoon S, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomized, double-blind phase 3 trial. Lancel Oncol. 2014;15:1195–1206.
   PubMed Web of Science ®Google Scholar
• Berdeja J, Hart L, Mace J, et al. Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma. Haematologica. 2015;100(5):670–676.
   PubMed Web of Science ®Google Scholar
• Kaufman J, Mina R, Jakubowiak AJ, et al. Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a multiple myeloma research consortium phase I study. Blood Cancer J. 2019;9:3.
   PubMed Web of Science ®Google Scholar
• Reu FJ, Valent J, Malek E, et al. A phase I study of ixazomib in combination with panobinostat and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood. 2015;126:4221.
   Web of Science ®Google Scholar
• Ocio EM, Vilanova D, Atadja P, et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica. 2010;95:794–803.
   PubMed Web of Science ®Google Scholar
• Mateos M, Spencer A, Taylor K, et al. Phase Ib study of oral panobinostat (LBH589) plus lenalidomide plus dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma. J Clin Oncol. 2010;25:8030.
   Google Scholar
• Chari A, Cho H, Dhadwal A, et al. A phase II study of oral panobinostat with lenalidomide and weekly dexamethasone in myeloma. Blood Adv. 2017;1(19):1575–1583.
   PubMed Web of Science ®Google Scholar
• Laubach J, Tuchman SA, Rosenblatt J, et al. Phase 1b study of panobinostat in combination with lenalidomide, bortezomib, and dexamethasone in relapsed refractory multiple myeloma. ASCO Meet Abstr. 2016;34:8014.
   Google Scholar
• Shah JJ, Feng L, Manasanch EE, et al. Phase I/II trial of the efficacy and safety of combination therapy with lenalidomide/bortezomib/dexamethasone (RVD) and panobinostat in transplant-eligible patients with newly diagnosed multiple myeloma. Blood. 2015;126:187.
   Google Scholar
• Berenson J, Hilger J, Yellin O, et al. A phase I/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma. Ann Hematol. 2014;93:88–98.
   Web of Science ®Google Scholar
• Offindi M, Polloni C, Cavallo F, et al. Phase II study of melphalan, thalidomide, and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. Leuk Lymphoma. 2012;53:1722–1727.
   PubMed Web of Science ®Google Scholar
• Patheon, Inc. Zolinza (vorinostat) package insert. Mississauga (ON); 2013.
   Google Scholar
• Hideshima T, Anderson KC. Histone deacetylase inhbitors in the treatment for multiple myeloma. Int J Hematol. 2013;97:324–332.
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Friedman EJ, Sandhu P, et al. Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor. Cancer Chemother Pharmacol. 2013;72:493–508.
   PubMed Web of Science ®Google Scholar
• Richardson P, Mitsiades C, Colson K, et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma. 2008;49(3):502–507.
   PubMed Web of Science ®Google Scholar
• Voorhees PM, Gasparetto C, Osman K, et al. Results of a phase I study of vorinostat in combination with pegylated liposomal doxorubicin and bortezomib in patients with relapsed/refractory multiple myeloma. [Abstract #1955]. Presented at the 53rd ASH Annual Meeting and Exposition; 2011 Dec 10–13; San Diego, CA.
   Google Scholar
• Weber DM, Graef T, Hussein M, et al. Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012;12:319–324.
   PubMed Web of Science ®Google Scholar
• Siegel DS, Dimopoulos M, Jagannath S, et al. VANTAGE 095: an international, multicenter, open-label study of vorinostat (MK-0683) in combination with bortezomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2016;16(6):329–334.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Siegel DS, Lonial S, et al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomized, dou- ble-blind study. Lancet Oncol. 2013;14:1129–1140.
   PubMed Web of Science ®Google Scholar
• Siegel DS, Richardson P, Dimopoulos M, et al. Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood Cancer J. 2014;4:e182.
   PubMed Web of Science ®Google Scholar
• Vesole DH, Bilotti E, Richter JR, et al. Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma. Br J Haematol. 2015;171:52–59.
   PubMed Web of Science ®Google Scholar
• Santo L, Hideshima T, Kung AL, et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood. 2012;119(11):2579–2589.
   PubMed Web of Science ®Google Scholar
• Vogl DT, Raje N, Jagannath S, et al. Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. Clin Cancer Res. 2017;23(13):3307–3315.
   PubMed Web of Science ®Google Scholar
• Vogl DT, Raje NS, Jagannath S, et al. Ricolinostat (ACY-1215), the first selective HDAC6 inhibitor, in combination with bortezomib and dexamethasone in patients with relapsed or relapsed-and-refractory multiple myeloma: phase 1b results (ACY-100 Study). Blood. 2015;126:1827.
   Web of Science ®Google Scholar
• Raje NS, Bensinger W, Cole C, et al. Ricolinostat (ACY-1215), the first selective HDAC6 inhibitor, combines safely with pomalidomide and dexamethasone and shows promosing early results in relapsed-and-refractory myeloma (ACE-MM-102 study). Blood. 2015;126:4228.
   Web of Science ®Google Scholar
• Yee AJ, Bensinger WI, Supko JG, et al. Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. Lancet Oncol. 2016;17:1569–1578.
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Richardson PG, Gabrail NY, et al. HDAC6 selective inhibitor: synergy with immunomodulatory (IMID) drugs in multiple myeloma cells and early clinical results (ACE-MM-200 study). Blood. 2015;126:3040.
   Google Scholar
• Bishton M, Harrison S, Martin B, et al. Deciphering the molecular and biological processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. Blood. 2012;117:3658–3668.
   Web of Science ®Google Scholar
• Badros A, Burger AM, Philip S, et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res. 2009;15(16):5250–5257.
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Ely S, Tomer M, et al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer. 2011;117:336–342.
   PubMed Web of Science ®Google Scholar
• Harrison S, Quach H, Link E, et al. A high rate of durable responses with romidepsin, bortezomib and dexamethasone in relapsed or refractory multiple myeloma. Blood. 2011;118:6274–6283.
   PubMed Web of Science ®Google Scholar
• Steele NL, Plumb JA, Vidal L, et al. A phase 1, pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat (PXD101) in patients with advanced solid tumors. Clin Cancer Res. 2008;14:804–810.
   PubMed Web of Science ®Google Scholar
• Gimsing P, Hansen M, Knudsen LM, et al. A phase 1 clinical trail of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol. 2008;81:170–176.
   PubMed Web of Science ®Google Scholar
• Sullivan D, Shingal S, Chuster M, et al. A phase II study of PXD101 in advanced multiple myeloma. Blood. 2006;108(1):00–000. Abstract 3583.
   Google Scholar
• Moreau P, Facon T, Touzeau C, et al. Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma. Leukemia&Lymphoma. 2016;57(7):1546–1559.
   PubMed Web of Science ®Google Scholar
• Zhang S, Suvannasankha A, Crean C, et al. The novel histone deacetylase inhibitor, AR-42, inhibits gp130/stat3 pathways and induces apoptosis and cell cycle arrest in multiple myeloma cells. Int J Cancer. 2011;129:204–213.
   PubMed Web of Science ®Google Scholar